EPISODE · Jun 8, 2026 · 20 MIN
How Weight Loss Drugs Are Reshaping What We Eat And Drink
from Beer In Front · host Dave Zalatoris
What happens when millions of people simply stop wanting that second beer? In this episode of Beer In Front, I take a deep dive into the rapidly growing world of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound—and explore how these drugs are reshaping the food and beverage industry. While most coverage focuses on weight loss, the bigger story may be changing consumer behavior. Research suggests GLP-1 medications don't just reduce appetite, they may also reduce cravings for alcohol, snacks, and other highly rewarding foods by affecting the brain's dopamine reward system. Why GLP-1 users are drinking significantly less alcoholNew research showing dramatic reductions in alcohol cravingsHow wine, beer, and spirits are being affected differentlyWhy bars and restaurants are seeing smaller checks and fewer repeat drink ordersThe projected $30-$55 billion impact on the food and beverage industryHow grocery shopping habits are changingThe opportunities for premium alcohol, craft beverages, and non-alcoholic alternativesWhy GLP-1 medications could become an important tool in treating alcohol use disorderWhat breweries, bars, restaurants, and food companies need to do to adaptAs adoption continues to grow and new oral versions of these medications reach the market, the effects on consumer spending and consumption habits may only accelerate.Whether you're in the beer business, restaurant industry, food manufacturing, or simply curious about how emerging health trends shape the economy, this episode explores one of the most important consumer shifts happening today.Statistic Sources1 in 8 U.S. adults currently on a GLP-1 drug KFF Health Tracking Poll, Nov 2025Up to 75% potential reduction in alcohol consumption Morgan Stanley 25% of GLP-1 users stopped drinking entirely Morgan Stanley41% reduction in daily drinking (clinical trial) JAMA Psychiatry2025 Wine down 52%, beer 43%, spirits 40% EY-Parthenon Survey10% of adults = 50% of all alcohol sold U.S. alcohol consumption data$30–55B projected F&B revenue loss by 2030–34 J.P. MorganFeb 2026 23% of households contain a GLP-1 user CNBC / industry data2026 Dinner traffic down 6% among regular users Restaurant industry analysis, 2026Become a supporter of this podcast: https://www.spreaker.com/podcast/beer-in-front--5704447/support.Beer Media Group
What this episode covers
What happens when millions of people simply stop wanting that second beer? In this episode of Beer In Front, I take a deep dive into the rapidly growing world of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound—and explore how these drugs are reshaping the food and beverage industry. While most coverage focuses on weight loss, the bigger story may be changing consumer behavior. Research suggests GLP-1 medications don't just reduce appetite, they may also reduce cravings for alcohol, snacks, and other highly rewarding foods by affecting the brain's dopamine reward system. Why GLP-1 users are drinking significantly less alcoholNew research showing dramatic reductions in alcohol cravingsHow wine, beer, and spirits are being affected differentlyWhy bars and restaurants are seeing smaller checks and fewer repeat drink ordersThe projected $30-$55 billion impact on the food and beverage industryHow grocery shopping habits are changingThe opportunities for premium alcohol, craft beverages, and non-alcoholic alternativesWhy GLP-1 medications could become an important tool in treating alcohol use disorderWhat breweries, bars, restaurants, and food companies need to do to adaptAs adoption continues to grow and new oral versions of these medications reach the market, the effects on consumer spending and consumption habits may only accelerate.Whether you're in the beer business, restaurant industry, food manufacturing, or simply curious about how emerging health trends shape the economy, this episode explores one of the most important consumer shifts happening today.Statistic Sources1 in 8 U.S. adults currently on a GLP-1 drug KFF Health Tracking Poll, Nov 2025Up to 75% potential reduction in alcohol consumption Morgan Stanley 25% of GLP-1 users stopped drinking entirely Morgan Stanley41% reduction in daily drinking (clinical trial) JAMA Psychiatry2025 Wine down 52%, beer 43%, spirits 40% EY-Parthenon Survey10% of adults = 50% of all alcohol sold U.S. alcohol consumption data$30–55B projected F&B revenue loss by 2030–34 J.P. MorganFeb 2026 23% of households contain a GLP-1 user CNBC / industry data2026 Dinner traffic down 6% among regular users Restaurant industry analysis, 2026Become a supporter of this podcast: https://www.spreaker.com/podcast/beer-in-front--5704447/support.Beer Media Group
NOW PLAYING
How Weight Loss Drugs Are Reshaping What We Eat And Drink
No transcript for this episode yet
Similar Episodes
Dec 5, 2025 ·50m
Oct 9, 2025 ·33m
Oct 3, 2025 ·40m
Sep 11, 2025 ·31m
Aug 27, 2025 ·39m
Aug 18, 2025 ·54m